Rapport Therapeutics (NASDAQ:RAPP) Reaches New 1-Year Low – Here’s Why

Rapport Therapeutics (NASDAQ:RAPP)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $12.98 and last traded at $13.97, with a volume of 141904 shares changing hands. The stock had previously closed at $14.81.

Rapport Therapeutics Stock Performance

The business’s fifty day moving average price is $20.46.

Institutional Trading of Rapport Therapeutics

A number of institutional investors have recently modified their holdings of the business. FMR LLC raised its holdings in Rapport Therapeutics by 10.1% during the 3rd quarter. FMR LLC now owns 5,486,468 shares of the company’s stock valued at $112,363,000 after acquiring an additional 503,117 shares during the period. ARCH Venture Management LLC purchased a new stake in Rapport Therapeutics during the 2nd quarter worth about $86,730,000. Johnson & Johnson bought a new position in Rapport Therapeutics in the 2nd quarter worth about $58,105,000. Sofinnova Investments Inc. bought a new stake in shares of Rapport Therapeutics during the second quarter valued at about $45,393,000. Finally, Perceptive Advisors LLC bought a new stake in shares of Rapport Therapeutics during the second quarter valued at about $17,403,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.